Dr. Janet Greeson, CEO of Samaritan stated, ``We
are extremely pleased the FDA has cleared our IND.
We have high hopes for Cushing's syndrome SP-6300's
ability to modulate pathologically high cortisol
levels since it demonstrated proof of concept as
a cortisol modulator in Samaritan's Phase II clinical
HIV trial. We believe SP-6300 can offer a unique
and novel approach for a broad range of applications
where cortisol levels get out of control.''
Cortisol
is important as it performs vital tasks in the body
but when it is too high or too low, it can cause
physical problems. It helps maintain blood pressure
and cardiovascular function, reduces the immune
system's inflammatory response, balances the effects
of insulin in breaking down sugar for energy, and
regulates the metabolism of proteins, carbohydrates,
and fats.
About
SP-6300:
SP-6300
acts by reducing the levels of the rate-limiting
enzyme HMGCoA reductase mRNA, leading to reduced
activity and decreased cholesterol and corticosteroid
biosynthesis.
See
peer reviewed journal publications: http://www.samaritanpharma.com/publications_and_patents.asp
Samaritan
Pharmaceuticals: ``Transforming Today's Science
Into Tomorrow's Cures...''
Samaritan
Pharmaceuticals is a life science company focused
on commercializing its pipeline of innovative drugs
to relieve the suffering of patients with Alzheimer's,
cancer, heart disease, and infectious disease. Samaritan's
business strategy is to partner drug candidates
in its pipeline after Phase II (proof of concept)
human studies. Samaritan has executed its first
partnering agreement with Pharmaplaz, Ireland for
its PII, HIV drug SP-01A. In addition, Samaritan's
sales arm has acquired the marketing and sales rights
to sell ten revenue-generating products in Greece
and various Eastern European countries.
Website:
http://www.samaritanpharma.com.
Please register so we can notify you of upcoming
conference calls, news and events.
Disclaimer
The
company disclaims any information created by an
outside party and endorses only information communicated
by its press releases, filings, and Website. This
news release contains forward-looking statements
that reflect management's current beliefs about
the potential for its drug candidates, science,
and technology. However, as with any biopharmaceutical
under development, there are significant risks and
uncertainties in the process of development and
regulatory review. There are no guarantees that
products will prove to be commercially successful.
For additional information about the factors that
affect the company's business, please read the company's
latest Form 10-K filed April 13, 2007. The company
undertakes no duty to update forward-looking statements.
